TILATAMIG SAMROTECAN
UNII BL5C53FB6H

Substance Identification & Data

This profile provides standardized clinical and technical data for Tilatamig Samrotecan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) BL5C53FB6H.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2868265-77-2 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

BL5C53FB6H

CAS Registry Number

2868265-77-2

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

TILATAMIG SAMROTECAN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C192091

National Cancer Institute reference terminology for clinical and research data.

INN ID

13021

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

NO-14

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Tilatamig Samrotecan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

Common Names & Synonyms

IMMUNOGLOBULIN G1 (133-CYSTEINE,227-VALINE,241-PHENYLALANINE,242-GLUTAMIC ACID,338-SERINE, 361-CYSTEINE,373-TRYPTOPHAN), ANTI-(HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR) (HUMAN MONOCLONAL RAA22 .GAMMA.1-CHAIN), (133->126'')-DISULFIDE WITH (126-CYSTEINE,216-VALINE) HUMAN MONOCLONAL RAA22 .LAMBDA.-CHAIN, (361->348')-DISULFIDE WITH IMMUNOGLOBULIN G1 (233-PHENYLALANINE,234-GLUTAMIC ACID,330-SERINE,348-CYSTEINE,365-SERINE,367-ALANINE,406-VALINE) ANTI-(HUMAN HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET) (HUMAN MONOCLONAL B09 .GAMMA.1-CHAIN) COMPLEX WITH HUMAN MONOCLONAL B09 .KAPPA.-CHAIN, 214'',219,225,228,233',236'-HEXAKIS(THIOETHER) WITH N-(31-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)-1,29-DIOXO-4,7,10,13,16,19,22,25-OCTAOXA-28-AZAHENTRIACONT-1-YL)-L-VALYL-N-((9S)-9-ETHYL-2,3,9,10,13,15-HEXAHYDRO-9-HYDROXY-10,13-DIOXO-1H,12H-BENZO(DE)PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLIN-4-YL)-L-ALANINAMIDE

IMMUNOGLOBULIN G1-KAPPA/G1-LAMBDA, ANTI-(HOMO SAPIENS MET (MET PROTO-ONCOGENE, HEPATOCYTE GROWTH FACTOR (HGF) RECEPTOR, HGFR, SCATTER FACTOR (SF) RECEPTOR, HGF/SF RECEPTOR, RECEPTOR TYROSINE-PROTEIN KINASE C-MET, PAPILLARY RENAL CELL CARCINOMA 2, RCCP2)) AND ANTI-(HOMO SAPIENS EGFR (EPIDERMAL GROWTH FACTOR RECEPTOR, RECEPTOR TYROSINE-PROTEIN KINASE ERBB-1, ERBB1, HER1, HER-1, ERBB)), HOMO SAPIENS MONOCLONAL ANTIBODY, BISPECIFIC, CONJUGATED ON 6 CYSTEINYL RESIDUES TO SAMROTECAN

TILATAMIG SAMROTECAN

TILATAMIG SAMROTECAN [INN]

TILATAMIG SAMTOTECAN [USAN]

External Clinical & Regulatory Resources

Previous UNIIBL5AGC2ESB

Next UNIIBL5GDJ2EUN